top of page
The Sound of Evolution
Alemtuzumab
Mechanism of action:
Alemtuzumab is a monoclonal antibody that binds to the CD52 protein. CD52 is expressed on T cells, B cells, monocytes, macrophages, and some natural killer cells. Once Alemtuzumab binds to CD52, it triggers complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC), leading other immune cells to destroy and eliminate the immune cells coated by Alemtuzumab.
Reference(s):
White AL et al. (2013). FcgammaRIotaIotaB controls the potency of agonistic anti-TNFR mAbs. Cancer Immunol Immunother.
bottom of page